{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:12:09Z","timestamp":1763626329449,"version":"3.45.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100026910","name":"Tucker Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Particle Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijpt.2025.101210","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:26:52Z","timestamp":1761413212000},"page":"101210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-5655","authenticated-orcid":false,"given":"Sherif G.","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Halthore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-6486","authenticated-orcid":false,"suffix":"Jr","given":"Curtiland","family":"Deville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpt.2025.101210_bib1","unstructured":"The Surveillance, E., and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2024 February 13, 2024; Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html\u3009."},{"issue":"6","key":"10.1016\/j.ijpt.2025.101210_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.6004\/jnccn.2009.0044","article-title":"Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance","volume":"7","author":"Chen","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ijpt.2025.101210_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.21873\/anticanres.15525","article-title":"SBRT in localized renal carcinoma: a review of the literature","volume":"42","author":"DE LA Pinta","year":"2022","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ijpt.2025.101210_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ijpt.2025.101210_bib5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijpt.2025.101210_bib6","article-title":"Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer","volume":"39","author":"Tran","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijpt.2025.101210_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2025.03.007","article-title":"Practical considerations for the treatment of primary renal cell carcinoma with SABR","author":"Yu","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"12","key":"10.1016\/j.ijpt.2025.101210_bib8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.euo.2025.01.001","article-title":"Results of stereotactic body radiation therapy for primary renal cell carcinoma in a large multicenter series","volume":"8","author":"Abancourt","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ijpt.2025.101210_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers9060066","article-title":"Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage\/repair","volume":"9","author":"Mohamad","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/acm2.12308","article-title":"Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning","volume":"19","author":"Baydoun","year":"2018","journal-title":"J Appl Clin Med Phys"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijrobp.2024.04.066","article-title":"Dose-effect relationship of kidney function after SABR for primary renal cell carcinoma: TROG 15.03 FASTRACK II","volume":"120","author":"Gaudreault","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijpt.2025.101210_bib14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1016\/j.ijpt.2025.101210_bib15","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.3390\/cancers14153815","article-title":"Relationship between dose prescription methods and local control rate in stereotactic body radiotherapy for early stage non-small-cell lung cancer: systematic review and meta-analysis","volume":"14","author":"Eriguchi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.radonc.2015.09.008","article-title":"Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy","volume":"118","author":"Guckenberger","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ijpt.2025.101210_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2020.03.005","article-title":"Correlating dose variables with local tumor control in stereotactic body radiation therapy for early-stage non-small cell lung cancer: a modeling study on 1500 individual treatments","volume":"107","author":"Klement","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ijpt.2025.101210_bib18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/cancers14040933","article-title":"Escalated maximum dose in the planning target volume improves local control in stereotactic body radiation therapy for T1-2 lung cancer","volume":"14","author":"Inagaki","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijpt.2025.101210_bib19","first-page":"3","article-title":"Proton SBRT is ready to move past uncertainties and towards improved clinical outcomes","volume":"9","author":"Simone","year":"2023","journal-title":"J Radiosurg SBRT"},{"issue":"1","key":"10.1016\/j.ijpt.2025.101210_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1186\/s12885-025-14486-1","article-title":"Prospective phase II study of stereotactic body proton therapy for treatment of primary renal cell carcinoma (SPARE): clinical trial protocol","volume":"25","author":"Shaaban","year":"2025","journal-title":"BMC Cancer"}],"container-title":["International Journal of Particle Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518025004755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518025004755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:07:52Z","timestamp":1763626072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2331518025004755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"alternative-id":["S2331518025004755"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpt.2025.101210","relation":{},"ISSN":["2331-5180"],"issn-type":[{"type":"print","value":"2331-5180"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Particle Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpt.2025.101210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Particle Therapy Co-operative Group.","name":"copyright","label":"Copyright"}],"article-number":"101210"}}